Valley Fever Is Breaking Records in Arizona — And Scientists Say Climate Change Is Expanding Its Range Across the American Southwest

For most Americans, Valley Fever is either unknown or easily dismissed as a regional desert curiosity — a lung infection that affects people in Arizona and California, easily confused with pneumonia, unlikely to cause serious harm. That assumption is increasingly dangerous. Arizona reported nearly 15,000 cases of coccidioidomycosis — the scientific name for Valley Fever — in 2024, marking the most in state history and more than 34% above the five-year annual median. It is the latest in a string of record-setting years that reflects a convergence of factors: a warming, drying climate, explosive residential and commercial construction that disturbs soil where the pathogen lives, urban population growth into previously uninhabited desert, and a diagnosis rate that may still be significantly undercounting the true burden of disease. Valley Fever is now being detected in states that were not historically considered endemic, and scientists are warning that its geographic reach will expand substantially in coming decades.

Coccidioidomycosis is caused by Coccidioides immitis and Coccidioides posadasii, fungal pathogens that live in the arid and semiarid soils of the American Southwest and parts of Mexico, Central America, and South America. The spores of the fungus — called arthroconidia — are released into the air when dry soil is physically disturbed by wind, agricultural machinery, or construction equipment. Once inhaled, the spores convert to the parasitic form of the organism inside the human lung and begin to replicate. The result, in the majority of cases, is a flu-like illness that resolves without specific treatment. But for up to 40% of those infected, the disease progresses to symptomatic pulmonary infection resembling pneumonia. In approximately 5 to 10% of cases, the fungus disseminates beyond the lungs — spreading to the bones, joints, skin, meninges, or brain — producing a potentially fatal systemic infection that requires months to years of antifungal therapy.

The Numbers Behind Arizona's Record-Breaking Outbreak

In 2024, Arizona confirmed 14,787 cases of Valley Fever — more than 58% of the national total. The CDC's national surveillance data recorded 14,937 Valley Fever reports through August 10, 2024 alone, a 43% increase compared to the same period in 2023. California followed with 5,876 cases, accounting for 39% of the national total. Together, Arizona and California account for 97% of all reported coccidioidomycosis cases in the United States, though the disease has now been diagnosed in at least 18 states, including some — like Washington, Idaho, and parts of the Midwest — that have no known endemic soil populations of the fungus.

In Arizona's Pima County alone — which encompasses Tucson — nearly 1,600 cases were recorded in 2024, with 2025 numbers tracking at similar levels. The state averages more than 5,000 reported cases per year even in non-record years, along with approximately 700 hospitalizations and 50 deaths. At the national level, coccidioidomycosis accounts for an average of 200 deaths per year based on CDC mortality data from 1999 to 2023. Because Valley Fever is not uniformly reportable across all states and is frequently misdiagnosed as bacterial pneumonia — resulting in ineffective antibiotic treatment — researchers universally agree that documented case counts represent a significant undercount of actual disease burden.

The Construction Boom Is Feeding the Outbreak

Phoenix and Tucson are among the fastest-growing major metropolitan areas in the United States, and their growth is directly correlated with Valley Fever risk. The spores of Coccidioides are most efficiently aerosolized when large volumes of previously undisturbed desert soil are mechanically broken up — exactly what occurs when bulldozers grade land for housing subdivisions, solar farms, data centers, roadways, and commercial developments. The Phoenix metropolitan area has added hundreds of thousands of new residents over the past decade, each requiring new infrastructure built on desert soils where the fungus is endemic.

Construction workers, agricultural laborers, landscapers, archaeological field workers, and military personnel stationed in the Southwest are at significantly elevated occupational exposure risk. A man whose Valley Fever infection resulted in amputation of his arm was reported by Fox 10 Phoenix in December 2025, serving as a stark reminder of the disseminated disease's capacity to destroy tissue and bone. Unlike most respiratory diseases, Valley Fever cannot be prevented by a mask alone — standard surgical or N95 masks do not reliably prevent inhalation of arthroconidia, whose small particle size allows penetration into the lower respiratory tract.

Climate Change Is Expanding the Fungus's Territory

The scientific literature on Coccidioides ecology increasingly points to climate change as a major driver of the disease's geographic expansion. The fungus thrives in hot, dry conditions — specifically in soils with low moisture content and high ambient temperatures. Climate projections for the American Southwest forecast exactly those conditions: longer drought periods, hotter summers, reduced average annual precipitation, and increased frequency of the extreme drying events that create ideal arthroconidia dispersal conditions. A 2025 analysis published in the Infectious Disease Society of America's journal concluded that "increased awareness is needed as climate change could spread Valley Fever," and projected that the endemic range of Coccidioides would extend northward into parts of the Great Plains and Pacific Northwest within the coming decades.

A study published in the CDC's Morbidity and Mortality Weekly Report in February 2026 specifically documented regional increases in the incidence of coccidioidomycosis in Arizona between 2005 and 2022, using state health data to trace the upward trend line across nearly two decades. The data confirms that the current outbreak is not a random fluctuation but the product of sustained, long-term increase driven by environmental and demographic changes that are ongoing and accelerating.

The Diagnosis Problem: Why Cases Are Missed and What It Costs

Valley Fever's most insidious public health characteristic is its near-perfect mimicry of other common respiratory illnesses. In the Phoenix and Tucson metropolitan areas, Coccidioides causes an estimated 15% to 30% of all community-acquired pneumonias — yet providers frequently fail to test for it, instead prescribing antibiotics that have no effect on a fungal infection. The diagnostic delay extends patient suffering, increases complication rates, generates unnecessary healthcare costs, and permits ongoing community exposure from misdiagnosed patients who continue normal activity.

Arizona has mounted Valley Fever Awareness Week campaigns specifically designed to change clinician behavior — encouraging providers in urgent care, emergency medicine, and primary care to include coccidioidomycosis testing whenever a patient presents with respiratory illness in an endemic region. Thomas Williamson, Valley Fever epidemiologist with the Arizona Department of Health Services, has publicly attributed part of the 2024 case count increase to improved testing rates — which is simultaneously good news (more cases being correctly identified) and evidence of how massively the true burden was previously undercounted.

A Vaccine on the Horizon — But Not Yet Available

For the first time in decades, a Valley Fever vaccine appears to be approaching clinical viability. The University of Arizona's Valley Fever Center for Excellence has been a leader in vaccine research, and a dog-specific vaccine was reported in late 2025 as a milestone that could accelerate human vaccine development timelines. Human trials have been initiated for at least one Valley Fever vaccine candidate. However, no approved human vaccine is likely to be available before the end of this decade — leaving currently exposed populations dependent on awareness, early diagnosis, and antifungal treatment as their primary defenses.

The conclusion drawn from Arizona's 2024 data, the MMWR trend analysis, and the climate science converges on an uncomfortable but unavoidable message: Valley Fever is no longer a remote desert problem. It is a growing urban, occupational, and climate-driven health crisis in one of America's fastest-growing regions. Without a vaccine, without uniform reportability across all 50 states, and without mandatory occupational protections for construction workers in endemic zones, the record-setting years will continue — and the geographic boundaries of risk will continue to expand.

References

▪ 13 News KOLD – Valley Fever Cases Hit Record High in Arizona in 2024, Nov 14, 2025
▪ CDC – Reported Cases of Valley Fever: National Data and Statistics
▪ MMWR Feb 19, 2026 – Regional Increases in Incidence of Coccidioidomycosis, Arizona 2005-2022
▪ Outbreak News Today – Valley Fever Cases Up 43% in the US Through Mid-August 2024
▪ Maricopa County – Valley Fever Data and Reports 2025-2026
▪ Arizona DHS – Valley Fever Awareness Week and Annual Case Data
▪ Valley Fever Center for Excellence – News and Research Updates

Related Articles on ScienceTimes.com

▶ The Fungus in the Dirt: How Coccidioides Survived the Ice Age — and Is Thriving in a Warming World
▶ Misdiagnosed as Pneumonia: How Valley Fever's Invisibility Costs Lives and Billions in Healthcare Dollars
▶ Valley Fever Vaccine Research: How Close Are Scientists to Stopping America's Fastest-Growing Fungal Disease?
▶ Construction Boom, Desert Soil, and Rising Temperatures: The Recipe for Arizona's Worst Outbreak on Record